<table id="table16" width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16	Amino Acid Substitutions in Viremic Subjects Across HBV Trials of VIREAD</caption>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<thead>
<tr>
<th stylecode="Rrule"></th>
<th colspan="3" stylecode="Botrule Rrule">Compensated Liver Disease</th>
<th rowspan="2">Decompensated Liver Disease  (N=39)<footnote id="table16d">Subjects with decompensated liver disease from Study 0108 (N=39) receiving up to 48 weeks of treatment with VIREAD.</footnote>
</th>
</tr>
<tr>
<th stylecode="Rrule"></th>
<th stylecode="Rrule">Nucleotide-Naïve      (N=417)<footnote>Nucleotide-naïve subjects from Studies 0102 (N=246) and 0103 (N=171) receiving up to 384 weeks of treatment with VIREAD.</footnote>
</th>
<th stylecode="Rrule">HEPSERA-Experienced (N=247)<footnote>HEPSERA-experienced subjects from Studies 0102/0103 (N=195) and 0106 (N=52) receiving up to 336 weeks of treatment with VIREAD after switching to VIREAD from HEPSERA. Study 0106, a randomized, double-blind, 168-week Phase 2 trial, has been completed.</footnote>
</th>
<th stylecode="Rrule">Lamivudine- Resistant (N=136)<footnote id="table16c">Lamivudine-resistant subjects from Study 0121 (N=136) receiving up to 96 weeks of treatment with VIREAD after switching to VIREAD from lamivudine.</footnote>
</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Rrule">Viremic at Last Time Point on VIREAD</td>
<td stylecode="Rrule" valign="middle">38/417 (9%)</td>
<td stylecode="Rrule" valign="middle">37/247 (15%)</td>
<td stylecode="Rrule" valign="middle">9/136 (7%)</td>
<td valign="middle">7/39 (18%)</td>
</tr>
<tr>
<td stylecode="Rrule">Treatment-Emergent Amino Acid Substitutions<footnote>Denominator includes those subjects who were viremic at last time point on VIREAD monotherapy and had evaluable paired genotypic data.</footnote>
</td>
<td stylecode="Rrule" valign="middle">18<footnote>Of the 18 subjects with treatment-emergent amino acid substitutions during Studies 0102 and 0103, 5 subjects had substitutions at conserved sites and 13 subjects had substitutions only at polymorphic sites, and 8 subjects had only transient substitutions that were not detected at the last time point on VIREAD.</footnote>/32 (56%)</td>
<td stylecode="Rrule" valign="middle">11<footnote>Of the 11 HEPSERA-experienced subjects with treatment-emergent amino acid substitutions, 2 subjects had substitutions at conserved sites and 9 had substitutions only at polymorphic sites.</footnote>/31 (35%)</td>
<td stylecode="Rrule" valign="middle">6<footnote id="table16h">Of the 6 lamivudine-resistant subjects with treatment-emergent substitutions during Study 0121, 3 subjects had substitutions at conserved sites and 3 had substitutions only at polymorphic sites.</footnote>/8 (75%)</td>
<td valign="middle">3/5 (60%)</td>
</tr>
</tbody>
</table>